Sagimet Biosciences Inc. (SGMT) stock
SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.22−0.71 (-6.50%)
Close on Nov 13, 2026Market cap $635.26MP/E –Yield –
Sagimet Biosciences cash
Cash and short-term investments held at the end of each period.
Sagimet Biosciences's cash was $275.80M at Sep 30, 2026. For fiscal 2025 it was $113.10M, down 28.7% from the year before. The highest annual figure on record is $158.70M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.10M | -28.7% |
| FY2024 | Dec 31, 2024 | $158.70M | +67.2% |
| FY2023 | Dec 31, 2023 | $94.90M | +193.4% |
| FY2022 | Dec 31, 2022 | $32.35M | -43.0% |
| FY2021 | Dec 31, 2021 | $56.73M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $275.80M | +119.8% |
| Q2 FY2026 | Jun 30, 2026 | $257.60M | +90.1% |
| Q1 FY2026 | Mar 31, 2026 | $104.50M | -27.7% |
| Q4 FY2025 | Dec 31, 2025 | $113.10M | -28.7% |
| Q3 FY2025 | Sep 30, 2025 | $125.50M | -26.2% |
| Q2 FY2025 | Jun 30, 2025 | $135.50M | -28.1% |
| Q1 FY2025 | Mar 31, 2025 | $144.60M | -25.3% |
| Q4 FY2024 | Dec 31, 2024 | $158.70M | +67.2% |
| Q3 FY2024 | Sep 30, 2024 | $170.00M | +66.9% |
| Q2 FY2024 | Jun 30, 2024 | $188.50M | +918.9% |
| Q1 FY2024 | Mar 31, 2024 | $193.70M | +1469.9% |
| Q4 FY2023 | Dec 31, 2023 | $94.90M | +193.4% |
| Q3 FY2023 | Sep 30, 2023 | $101.84M | +4466.9% |
| Q2 FY2023 | Jun 30, 2023 | $18.50M | +314.4% |
| Q1 FY2023 | Mar 31, 2023 | $12.34M | -78.3% |
| Q4 FY2022 | Dec 31, 2022 | $32.35M | – |
| Q3 FY2022 | Sep 30, 2022 | $2.23M | – |
| Q2 FY2022 | Jun 30, 2022 | $4.46M | – |
| Q4 FY2021 | Dec 31, 2021 | $56.73M | – |
See a number that looks wrong?